K. Sjoquist

Publications84
h-index15
Citations1,998
Highly Influential Citations73
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • E. Van Cutsem
  • 553 Publications, 77,566 Citations
  • N. Tebbutt
  • 287 Publications, 13,004 Citations
  • A. Ohtsu
  • 580 Publications, 18,481 Citations
  • J. Valle
  • 446 Publications, 10,832 Citations
  • Publications
  • Influence
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
BACKGROUND In a previous meta-analysis, we identified a survival benefit from neoadjuvant chemotherapy or chemoradiotherapy before surgery in patients with resectable oesophageal carcinoma. We… Expand
  • 1,219
  • 45
  • PDF
Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
Purpose: Personalized medicine strategies using genomic profiling are particularly pertinent for pancreas cancer. The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial was initially… Expand
  • 151
  • 5
  • PDF
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
PURPOSE We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. PATIENTS AND METHODS We conducted an international (Australia and New Zealand,… Expand
  • 107
  • 3
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
Objective A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor… Expand
  • 5
  • 3
  • PDF
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
Background:This randomised phase II study evaluated the efficacy and safety of panitumumab added to docetaxel-based chemotherapy in advanced oesophagogastric cancer.Methods:Patients with metastatic… Expand
  • 30
  • 2
Symptom Burden and Outcomes of Patients With Platinum Resistant/Refractory Recurrent Ovarian Cancer: A Reality Check
Background The aim of chemotherapy in patients with platinum resistant ovarian cancer is palliation. Patients’ experience of symptoms is not well documented, and the impact of treatment on symptoms… Expand
  • 18
  • 2
Advances in Molecular Pathology and Treatment of Periampullary Cancers
Objectives Periampullary cancers (PACs) include the following 4 traditional anatomic subtypes: pancreatic, ampullary, biliary, or duodenal cancers. This review was performed to highlight recent… Expand
  • 14
  • 2
INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials…
4003 Background: REG is an oral multi-kinase inhibitor warranting evaluation in AOGC following failure of 1st or 2nd line chemotherapy (CT) where few options exist. Methods: International (Australia… Expand
  • 27
  • 1
Chemotherapy and radiotherapy for advanced pancreatic cancer.
BACKGROUND Pancreatic cancer (PC) is a highly lethal disease with few effective treatment options. Over the past few decades, many anti-cancer therapies have been tested in the locally advanced and… Expand
  • 45
  • 1
A serious complication of selected internal radiation therapy: case report and literature review.
The use of selective internal radiation therapy (SIRT) with SIR-Spheres(R) (Sirtex, Sydney, Australia) is increasingly recognized as a potential therapeutic modality of primary and secondary… Expand
  • 40
  • 1